Your browser doesn't support javascript.
loading
Gene Therapies for Retinitis Pigmentosa that Target Glucose Metabolism.
Xue, Yunlu; Cepko, Constance L.
Affiliation
  • Xue Y; Lingang Laboratory, Shanghai 200031, China ylxue@lglab.ac.cn cepko@genetics.med.harvard.edu.
  • Cepko CL; Departments of Genetics and Ophthalmology, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115, USA ylxue@lglab.ac.cn cepko@genetics.med.harvard.edu.
Article de En | MEDLINE | ID: mdl-37460158
ABSTRACT
Retinitis pigmentosa is a blinding disease wherein rod photoreceptors are affected first, due to the expression of a disease gene, leading to the loss of dim light vision. In many cases, cones do not express the disease gene, yet they are also affected and eventually die, typically after most of the rods in their neighborhood have died. The cause of secondary cone death is unclear. Photoreceptors are one of the most energy-demanding cell types in the body and consume a high amount of glucose. At an early stage of degeneration, the cones appear to have a shortage of glucose to fuel their metabolism. This review focuses on gene therapy approaches that address this potential metabolic shortcoming.

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cold Spring Harb Perspect Med Année: 2023 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Cold Spring Harb Perspect Med Année: 2023 Type de document: Article